CTOs on the Move

The Headline Salon- Hair Salons

www.theheadlinesalon.com

 
The Headline Salon- Hair Salons is a Woodland Hills, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

ChemNavigator

At ChemNavigator we help research organizations identify and procure the chemistry they need for drug discovery and agrochemical research. We serve researchers in medicinal, computational, and synthetic chemistry as well as chemical procurement

HiFiBiO - High Fidelity Biology

HiFiBiO SAS commercializes proprietary single cell technologies for applications in drug and biomarker discovery and development.

Pharma Connections Worldwide

Pharma Connections Worldwide is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Rapid Pathogen Screening

Founded in 2004, Rapid Pathogen Screening is an emerging developer, manufacturer, and marketer of rapid point-of-care (POC) diagnostic tests. The company’s innovative and patented technology platform facilitates the development of a spectrum of cost-effective tests to rapidly identify patients with infectious diseases and inflammatory conditions. As a result of U.S. government contracts, this platform is also being used to develop tests for bio-terrorism and chemical nerve agent blood toxins. RPS tests have high sensitivity and specificity, and can be easily performed by a clinician or their staff without extensive training or additional equipment.

Imvax

The approach is an autologous, cell-based treatment that activates the full array of patient-specific antigens, resulting in both an innate and adaptive immune response. The company`s lead program is in glioblastoma multiforme (GBM), an extremely aggressive form of brain cancer with a significant unmet need. In parallel, the company is also progressing the platform in a select number of additional solid tumors where the unmet need remains great and where initial immunotherapy approaches have often failed to provide a significant benefit.